Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter ended 30 June 2022. The above information shall be made available on the website of the Company at www.tatvachintan.com. This is for your information and records. Tatva Chintan Pharma Chem Ltd - 543321 - Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended On 30 June 2022
Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2022. The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 25 July 2022. Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations. The above information shall be made available on the website of the Company at www.tatvachintan.com. The Board meeting commenced at 11:30 A.M. and concluded at 03:30 P.M. Kindly take above intimation on your record and oblige. Tatva Chintan Pharma Chem Ltd - 543321 - Board Meeting Outcome for Outcome Of The Board Meeting Held On 25.07.2022
Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2022. The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 25 July 2022. Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations. The above information shall be made available on the website of the Company at www.tatvachintan.com. The Board meeting commenced at 11:30 A.M. and concluded at 03:30 P.M. Kindly take above intimation on your record and oblige. Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we would like to inform you that the Earnings Call post announcement of financial results of the Company for the quarter ended 30 June 2022, is scheduled on Monday, 25 July 2022 at 05:00 pm IST. The Call is hosted by Haitong International and updated invite in this regard is attached for your information and records. The above information is also being made available on the website of the Company at www.tatvachintan.com. Kindly take above intimation on your record and oblige. Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we would like to inform you that the Earnings Call post announcement of financial results of the Company for the quarter ended 30 June 2022, is scheduled on Monday, 25 July 2022 at 05:00 pm IST. The Call is hosted by Haitong International and an invite in this regard is attached for your information and records. The above information is also being made available on the website of the Company at www.tatvachintan.com. Kindly take above intimation on your record and oblige. Tatva Chintan Pharma Chem Ltd - 543321 - Board Meeting Intimation for Consider, Approve And Take On Record The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended 30 June 2022.
Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/07/2022 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we hereby inform you that a meeting of the Board of Directors of Tatva Chintan Pharma Chem Limited is scheduled to be held on Monday, 25 July 2022, inter-alia, to consider, approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2022. Further, in accordance with the Company''s Code of Conduct for Prohibition of Insider Trading, the Company has intimated its ''''designated persons'''' regarding the closure of the Trading Window for trading in the Company''s equity shares from 01 July 2022 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Kindly take above intimation on your record and oblige Tatva Chintan Pharma Chem Ltd - 543321 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0220 Name of the Signatory :- ISHWAR NAYIDesignation :- Company Secretary and Compliance Officer Tatva Chintan Pharma Chem Ltd - 543321 - Intimation Under Regulation 30 Read With Point No. 8, Para B Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 read with Point No. 8, Para B of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Tatva Chintan Pharma Chem Ltd - 543321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 read with Schedule Ill of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Regulations') as amended. In accordance with the said Regulation, we wish to inform that CRISIL Ratings Limited has Reaffirmed the credit ratings of the Company as under: Facilities Rating Remarks Long Term Rating CRISIL A-/Stable No change Short Term Rating CRISIL A2+ No change The above information shall be uploaded on the website of the Company at www.tatvachintan.com. You are requested to kindly take the same on record.